@article{8014,
  keywords = {Adult, Antidepressive Agents, Conversion Disorder, Drug Resistance, Multiple, Bacterial, Female, Humans, Leprostatic Agents, leprosy, Treatment Outcome},
  author = {Legaspi PS and Abad Venida ML},
  title = {Conversion disorder: "an adverse reaction" to watch out for.},
  abstract = {<p>A subject was enrolled in a multicenter, double-blinded clinical trial of ofloxacin-containing multidrug therapy for leprosy by the World Health Organization in 1992 and she developed multiple physical symptoms a few hours after taking the regimen. Physical examination and laboratory work-ups could not support a medical diagnosis and she was eventually dropped from the study. Decoding revealed that she belonged in the control group given the World Health Organization/multiple drug therapy-multibacillary regimen. In the course of treatment, she was diagnosed with conversion disorder and was subsequently treated with an antipsychotic.</p>},
  year = {2008},
  journal = {Dermatologic clinics},
  volume = {26},
  pages = {239-43, vi},
  month = {2008 Apr},
  issn = {0733-8635},
  doi = {10.1016/j.det.2007.11.008},
  language = {eng},
}